To determine the effect of changing anticholinergic therapy in patients with COPD from ipratropium to tiotropium on pulmonary function. Methods: We examined records of patients prescribed high-dose ipratropium, who were subsequently converted to tiotropium. Spirometric values were obtained within 2 days of the change in medication and after 56 to 224 days of the switch to tiotropium. Results: 15 subjects were documented to have filled a prescription for ipratropium-containing medications the month prior to the change. Medication compliance over the 6 months prior to the switch in these patients was 72% ± 31% (mean ± SD) for ipratropium compared to 87% ± 14% for tiotropium over the 6-month period after the switch (P = 0.1). FEV 1 improved from 1.12 ± 0.39 L at baseline to 1.37 ± 0.49 L after the change to tiotropium (P = 0.01). FVC also improved from 2.45 ± 0.73 L at baseline to 2.72 ± 0.69 L after the change (P = 0.04). Maximal voluntary ventilation was also increased from 39.67 ± 10.7 L/min to 45.13 ± 15.8 L/min (P = 0.045).
Introduction
To date only smoking cessation or long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD) and resting hypoxemia have been shown to impact mortality in this disorder. 1, 2 However, some pharmacologic therapies impact a number of clinical parameters in patients with COPD. 2, 3 Currently there are 2 available inhaled anticholinergic medications, ipratropium and tiotropium, which improve air flow in patients with COPD. Tiotropium has a prolonged duration of action (24 hours) compared to ipratropium. 3 A recent study has suggested tiotropium is cost-effective compared to ipratropium. 4 Tiotropium has been shown to improve 1) forced expiratory volume in 1 second (FEV 1 ), 3 2) quality of life, and 3) exercise capacity and dyspnea compared to subjects treated with placebo or ipratropium. 5 Although these premarketing studies suggested an advantage of tiotropium over ipratropium in treatment of COPD patients there has not been any report of the effects of changing from ipratropium to tiotropium therapy in COPD patients followed in a general clinical setting.
Methods

selection of subjects
Clinical records were reviewed of patients followed in a specialized clinic for COPD at the Birmingham VAMC who were previously treated with a regimen that contained Records of 24 subjects who had spirometry performed on the day of the change from ipratropium to tiotropium were further examined. Four of these subjects had evidence of a COPD exacerbation on the day of the switch and were not evaluated leaving 20 subjects for further evaluation. When only subjects were included who had refilled the prescription for ipratropium containing medications in the month prior to the switch, to minimize noncompliance as a complicating issue, a total of 15 remained for final evaluation.
Calculation of medication compliance
The records of prescription refills were examined for each of the 15 subjects and the number of prescription refills of ipratropium over the 6 months prior to, or tiotropium over the 6 months after the switch were determined. The percentage of compliance with the respective medication was calculated by the number of months the medication was refilled in those 6 months. If the subject refilled the medication 6 times (all prescriptions were 1 month supply at a time) compliance was calculated as 100%.
Pulmonary function testing
Spirometry was performed by American Thoracic Society guidelines. 6 
statistical analysis
Differences between means were determined by T test. A P value less then 0.05 was considered significant.
Results subjects and medication compliance Table 1 shows demographics of the 15 subjects in the study.
Of the total number of subjects 15 patients had stage III, 2 subjects had stage IV and 4 subjects had stage II COPD as defined by GOLD. 7 All but 1 of the subjects had quit smoking. The average age for the 14 males and 1 female was 69.53 years. Compliance for anticholinergic use was 72% ± 31% (mean ± SD) for ipratropium 6 months prior to the switch compared to 87% ± 14% for tiotropium over the 6 month period after change in medication (P = 0.1). All patients were using the combination salmeterol/fluticasone inhaler Advair ® during the month prior to the anticholinergic switch and through the entire period of the study.
Pulmonary function testing Figure 1 shows individual data for the FEV 1 (A) and FVC (B) determined in the 15 subjects at baseline and after the change to tiotropium. FEV 1 increased by an average of 155 mL (12.8%) (P = 0.01). Five of the 15 subjects showed 
Discussion
Our study suggests replacing high-dose inhaled ipratropium with tiotropium significantly improves FVC and FEV 1 . The effect on FEV 1 suggests tiotropium has an advantage in improving airflow compared to high-dose ipratropium while effects of the change on FVC may be due to lessened air trapping.
A number of premarketing studies suggested tiotropium provides better bronchodilation compared to ipratropium administered 4 times a day and salmetrol administered twice a day, as evidenced by peak FEV 1 , trough FEV 1 and area under the curve. 3 However, in all of these studies the comparator group was treated with a lower dose of ipratropium then was employed in the current study. Ikeda et al demonstrated that increasing doses of ipratropium up to 240 µg had progressively beneficial effects on exercise capacity and FEV 1 . 8 The dose of ipratropium used in our study at each single treatment time was 114 µg, less than the optimal dose demonstrated in that study but more than comparator ipratropium arms in premarket studies of tiotropium. However, in clinical practice use of a higher dose of ipratropium to achieve a dose of 160 µg at each dosing time would be problematic because of the large number of 6 with tiotropium compared to placebo, ipratropium and long-acting β 2 -agonists. [9] [10] [11] [12] [13] Tiotropium was shown to improve FEV 1 regardless of the presence or absence of short-term improvement in FEV 1 .
14 Moreover, improvements in inspiratory capacity and FEV 1 with tiotropium in patients with hyperinflation are unrelated to small airway heterogeneity. 15 Tiotropium has also been shown to reduce dynamic hyperinflation resulting in improved exercise endurance. 3, 16, 17 Tiotropium has an excellent safety profile with dry mouth and urinary retention being the only major adverse events. 3, 13, [18] [19] [20] The incidence of dry mouth was slightly greater than that seen with ipratropium. 3 However, the effect was mild and did not lead to cessation of therapy. Serious adverse events occurred with the same frequency as in the control group. 3 A recently published meta-analysis of 17 randomized controlled trials raised concerns about an increased risk of cardiovascular death, myocardial infarction and stroke among COPD patients with use of inhaled anticholinergics (ipratropium or tiotropium). 21 However, the UPLIFT study did not demonstrate any such risks with long-term use of tiotropium. 22 Treatment with tiotropium is cost-effective compared to ipratropium. 4, 23 In a retrospective pooled analysis of longacting bronchodilators, treatment with tiotropium was shown to save US$391 per year while gaining 13 quality-adjusted days compared with ipratropium. 23 Since hospitalizations due to COPD exacerbations account for up to 70% of the medical care costs for COPD patients, reduction in hospitalizations is a major reason for cost-effectiveness of treatment with tiotropium. 24, 25 Our study suggests that tiotropium 18 µg in a once-daily regimen improves airway flow rates when compared to a previous regimen of 456 µg of ipratropium per day. This, and previous studies, suggest an advantage of long-acting anticholinergic agent over short-acting ipratropium. Larger studies may be needed to determine the "real world" physiologic and economic effect of changing from ipratropium to tiotropum as anticholinergic therapy.
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